XEN-D0501
As of the edition of 20 October 2026, XEN-D0501 is a drug: went quiet in 2018; acts on TRPV1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Unknown
- Registered trials
- 3, 0 stopped early
- Disease areas
- Hormones; Lungs and airways; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of XEN-D0501.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | Q8NER1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Xention | Lead sponsor of trials | 2014 to now |
| Pila Pharma | Lead sponsor of trials | 2017 to now |